| General Information | |
|---|---|
| ZINC ID | ZINC000013782512 |
| Molecular Weight (Da) | 344 |
| SMILES | CCCCC/C=CC/C=CC/C=CC/C=CCCCC1=N[C@H](C)CO1 |
| Molecular Formula | C23N1O1 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 114.126 |
| HBA | 2 |
| HBD | 0 |
| Rotatable Bonds | 14 |
| Heavy Atoms | 25 |
| LogP | 7.122 |
| Activity (Ki) in nM | 676.083 |
| Polar Surface Area (PSA) | 21.59 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | - |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | - |
| Plasma protein binding | 0.91315048 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 0 |
| Fraction csp3 | 0.61 |
| Ilogp | 5.35 |
| Xlogp3 | 7.19 |
| Wlogp | 6.57 |
| Mlogp | 5.24 |
| Silicos-it log p | 7.3 |
| Consensus log p | 6.41 |
| Esol log s | -7.48 |
| Esol solubility (mg/ml) | 0.0000181 |
| Esol solubility (mol/l) | 3.34E-08 |
| Esol class | Poorly sol |
| Ali log s | -8.25 |
| Ali solubility (mg/ml) | 0.00000305 |
| Ali solubility (mol/l) | 5.62E-09 |
| Ali class | Poorly sol |
| Silicos-it logsw | -12.04 |
| Silicos-it solubility (mg/ml) | 4.90E-10 |
| Silicos-it solubility (mol/l) | 9.04E-13 |
| Silicos-it class | Insoluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.5 |
| Lipinski number of violations | 2 |
| Ghose number of violations | 3 |
| Veber number of violations | 1 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.17 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 3.7 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -2.823 |
| Logd | 3.903 |
| Logp | 3.763 |
| F (20%) | 1 |
| F (30%) | 1 |
| Mdck | - |
| Ppb | 96.78% |
| Vdss | 3.54 |
| Fu | 3.21% |
| Cyp1a2-inh | 0.206 |
| Cyp1a2-sub | 0.762 |
| Cyp2c19-inh | 0.352 |
| Cyp2c19-sub | 0.133 |
| Cl | 3.653 |
| T12 | 0.893 |
| H-ht | 0.967 |
| Dili | 0.014 |
| Roa | 0.004 |
| Fdamdd | 0.81 |
| Skinsen | 0.965 |
| Ec | 0.009 |
| Ei | 0.193 |
| Respiratory | 0.913 |
| Bcf | 2.469 |
| Igc50 | 5.34 |
| Lc50 | 3.105 |
| Lc50dm | 4.121 |
| Nr-ar | 0.002 |
| Nr-ar-lbd | 0.004 |
| Nr-ahr | 0.002 |
| Nr-aromatase | 0.085 |
| Nr-er | 0.086 |
| Nr-er-lbd | 0.004 |
| Nr-ppar-gamma | 0.042 |
| Sr-are | 0.665 |
| Sr-atad5 | 0.01 |
| Sr-hse | 0.905 |
| Sr-mmp | 0.302 |
| Sr-p53 | 0.041 |
| Vol | 404.412 |
| Dense | 0.849 |
| Flex | 1.556 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 0 |
| Qed | 0.247 |
| Synth | 3.759 |
| Fsp3 | 0.609 |
| Mce-18 | 10.541 |
| Natural product-likeness | 1.003 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Accepted |
| Goldentriangle | Accepted |